Modality
Degrader
MOA
JAK1/2i
Target
EZH2
Pathway
Cell Cycle
MDD
Development Pipeline
Preclinical
~Nov 2020
→ ~Feb 2022
Phase 1
~May 2022
→ ~Aug 2023
Phase 2
Nov 2023
→ Dec 2028
Phase 2Current
NCT06988320
2,654 pts·MDD
2023-11→2028-12·Recruiting
2,654 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-12-162.7y awayPh2 Data· MDD
Trial Timeline
Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
P2
Recruit…
Catalysts
Ph2 Data
2028-12-16 · 2.7y away
MDD
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06988320 | Phase 2 | MDD | Recruiting | 2654 | UPCR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Fixanesiran | AbbVie | Preclinical | RET | |
| DSN-2247 | Daiichi Sankyo | NDA/BLA | EZH2 | |
| Motavorutinib | Amgen | Phase 3 | CDK4/6 | |
| VRT-9481 | Vertex Pharma | Phase 1/2 | Menin | |
| Sovarelsin | BioMarin | Phase 2 | CFTR | |
| Peminaritide | Sarepta | NDA/BLA | PLK4 | |
| HAL-9635 | Halozyme | Phase 2/3 | EZH2 | |
| Niramavacamten | Hansoh Pharma | Phase 2 | SGLT2 | |
| Talazumab | Zealand Pharma | Phase 1/2 | WEE1 | |
| CGO-9628 | CG Oncology | Phase 2/3 | AuroraA |